Board of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 2026

Date: 10.08.2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001. Scrip Code: 538965 Sub: Outcome of Board Meeting held on 10.08.2026 pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company was held on Monday, 10th August 2026, wherein the Board inter alia: 1. Considered and approved the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30th June, 2026. 2. The Board took note of the Limited Review Report issued by the Statutory Auditors of the Company on the aforesaid financial results. Further, the financial results are also available on the website of the Company at Concord Drugs Limited > Investor Relations and on the website of BSE Limited. The financial results will also be published in the newspapers as per the requirements and in the format prescribed under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 04:00 PM and concluded at 05:00 PM. This is for your information and records. Thanking you, Yours faithfully, For Concord Drugs Limited Nagi Reddy Seelam Managing Director DIN: 01764665 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th June 2026 Quarterly ended Year Ended 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 Particulars (Un Audited) ( Audited) (Un Audited) | _(Audited) I [Revenue from Operations a. Net sales from Operations 2,088.86 3555.22 133835 | 7.584.86 b. Other Operating Income 082 1.08 - 344 Il |Other Income il | Total Revenue (I+1l) 208968 3556.31 1.338.35 | 7.588.30 IV |Expenses a.Cost of Material Consumed 1,653.49 3,180.79 1,068.92 6,449.85 b. Changes in Inventories of finished goods, work-in-progress and stock-in-trad¢ 38.98 7.08 6064 63.98 . Employees Benefit Expenses 12457 17261 87.11 489.91 d. Finance Costs 35.11 34.46 41.99 145.91 . Depreciation and Amortisation expense 34.76 35.05 3655 135.72 f. Other expenses 48.52 52.85 2794 158.07 Total Expenses 1.935.42 3482.84 1,323.15 744344 Profit (Loss) before Exceptional item and tax (1ll-IV) 154.26 73.47 1520 144.86 Vv |Exceptional Items £ 2 VI [Profit/ (Loss) before tax (V-VI) 154.26 73.47 15.20 144.86 Vil |Tax Expense 43.04 21.79 4.06 4112 Vil |a. Currenttax 44.11 21.32 5.15 41.34 0 b. Deferred tax charge/credit -1.08 0.47 -1.09 -0.22 IX [Profit/ (Loss) for the period (VII-VIll) 111.23 51.68 1114 103.74 X |Other Comprenensive Income ot - - - Items that will not be reclassified to profit or loss - - - - Total Comprenensive Income for the period (comprising proft and other T o e o comprehensive income for the period) (IX+X) X1 |Pald up Capital 1317.50 131750 1,000.00 1317.50 (Face value of the share- Rs. 10 each) Other Equity 3645.12 3,533.89 2,422.50 3533.89 Xl |Earnings per share (of Rs. 10 each) (in Rupees) (not annualised) | (not annualised) | (not annualised) | (annualised) Xl |a. Basic (in Rs) 084 046 011 093 b Niluted (in Rs) na4 n4h 011 na3 Notes: [ The finnacial results of the company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies . Act, 2013, read with the relevant rules issued there under. 2 | The above standalone financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 10th August 2026 3 |Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation. | The EarningPesr Share (EPS) for the quarter ended is not strictly comparable on a Quarter-on-Quarter (QoQ) and Year-on-Year (YY) basis, as the weighted average number of equity shares outstanding increased during quarter ended 31.03.2026 pursuant to the allotment of 31,75,000 equity shares at @36.50 per share through a preferential issue. 4 |Notwithstanding the increase of over 33% in the Company’s equity share capital, the EPS has improved during the quarter. This improvement reflects the fact that the growth in profitability has more than outpaced the increase in the equity share base, demonstrating stronger earnings generation despite the dilution arising from the preterential allotment. 5 |The results are also available on the webiste of the Company www.concorddrugs.in By Urder of the Board For Concord Drugs Limited Nag! Reddy Seelam Place: Hyderabad Managing Director DIN: 01764665 Date: 10.08.2026 STATEMENT OF UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th June 2026 [Rs. in Lakhs] Quarterly ended Year Ended 30-Jun-26 31-Mar-26 30-Jun-25 | 31-Mar-26 Particulars (Un Audited) (Audited) (Un Audited) __ (Audited) I Revenue from Operations a. Net sales from Operations 2,093.88 3,788.80 1,360.64 7,873.68 b. Other Operating Income 0.82 1.08 - 3.44 Il [Other Income Il |Total Revenue (I+I1) 2,094.70 3,789.89 1,360.64 7.877.13 IV |Expenses a.Cost of Material Consumed 1,652.38 3,507.05 1,081.22 6,802.96 b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade| 38.98 -95.28 60.64 -38.37 c. Employees Benefit Expenses 12558 175.26 88.60 497.05 d. Finance Costs 39.61 39.57 49.00 171.37 e. Depreciation and Amortisation expense 34.93 35.28 36.78 136.67 f. Other expenses 48.73 53.24 28.55 160.13 Total Expenses 1,940.21 3,715.13 1,344.81 7,729.81 Profit/ (Loss) before Exceptional item and tax (11I-1V) 154.49 74.76 15.83 147.32 V |Exceptional ltems - - - - VI |Profit/ (Loss) before tax (V-VI) 154.49 74.76 15.83 147.32 VIl Tax Expense: 43.10 21.96 4.07 41.82 VIl |a. Current tax 44.15 21.66 5.34 41.98 0 |b. Deferred tax charge/credit -1.06 0.30 -1.27 -0.16 X [Profil/ (Luss) for the period (VI 111.40 52.80 177 105.50 X |Other Comprehensive Income g » - & Items that will not be reclassified to profit or loss. - - - - Total Comprehensive Income for the period (comprising profit and other fitm s260 AT - comprehensive income for the period) (IX+X) XI |Paid up Capital 1,317.50 1,317.50 1,000.00 1,317.50 (Face value of the share- Rs. 10 each) Other Equity 3,645.12 3,533.89 2422.50 3,533.89 XIl |Earnings per share (of Rs. 10 each)(in Rupees) (not annualised)| (not annualised)| (not annualised)| (annualised) Xl |a. Basic (in Rs) 0.85 047 0.12 0.95 b. Diluted (in Rs) 0.85 0.47 0.12 0.95 Notes: | [The finnacial results of the company have been prepared in accordance with the Indian Accounting Standards (ind AS) prescribed under section 133 of the |Companies Act, 2013, read with the relevant rules issued there under. , |The above Consolidated financial results as reviwed by the audit committee have been approved by Board of Directors atits meeting held on 10.08.2026 5 |Fisures of the corresponding previous periods are regrouped and reclassified whrever considered necessartyo correspond with current period's presentation. The Earnings Per Share (EPS) for the quarter ended is not strictly comparable on a Quarter-on-Quarter (QoQ) and Year-on-Year (YoY) basis, as the weighted average number of equity shares outstanding increased during quarter ended 31.03.2026 pursuant to the allotment of 31,75,000 equity shares at #36.50 per share through a preferential issue. 4 |Notwithstanding the increase of over 33% in the Company’s equity share capital, the EPS has improved during the quarter. This improvement reflects the fact that] tha frowth in profitahility has mara than outpaced the incraase in the equity share hase, demanstrating stranfer earnings fenaration daspita the dilution arising from the preferential allotment. 5 |T he results are also available on the webiste of the Company www.concorddrugs.in By Order of the Board For Concord Drugs Limited Nagi Reddy Seelar Place: Hyderabad Managing Director Date: 10.08.2026 DIN: 01764665 [Showing first 8,000 characters — download PDF for full document]